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Focal segmental glomerulosclerosis refers to a set of particular histopathologic lesions in which steroid-resistant podocyte injury
leads to patchy adhesions between the glomerular tuft and Bowman’s capsule, followed by progressive glomerulosclerosis and
proteinuric renalfailure.Becauseofthenonspeciﬁcnatureofthislesion,ithasbeen diﬃculttoclassifythevariousformsofprimary
nephrotic syndrome in children. However, with the recognition of hereditary FSGS caused by mutations podocyte slit diaphragm
genes, it is increasingly clear that the steroid-resistant form of FSGS that recurs in the renal allografts (R-FSGS) constitutes a
distinct clinical entity. Capitalizing on recent studies in which patients have been screened for slit diaphragm gene mutations, this
review focuses on the natural history and pathogenesis of R-FSGS.
1.R-FSGSinthe ContextofSteroid-Resistant
Nephrotic Syndrome
A recent population-based study in the Gironde region of
France reported an incidence of about 2.3 pediatric cases
of idiopathic nephrotic syndrome for every 100,000 children
<15 years of age [1]. The majority (91%) of these children
exhibited a classical steroid-responsive relapsing disease,
in which there may be podocyte foot process eﬀacement
noted on renal biopsy but no progressive renal insuﬃciency.
Estimates of steroid-responsiveness are somewhat lower
(80%) in referral populations or cohorts that include adults
[2] .A m o n gt h o s ew h of a i lt or e s p o n dt od a i l ys t e r o i dt h e ra p y
for 4 weeks, renal biopsies usually reveal a progressive lesion
in which early podocyte detachment from the glomerular
basement membrane is associated with segmental hyalinosis
of the glomerular capillary tuft and, eventually, ﬁbrotic
adhesions to Bowman’s capsule. It is the patchy distribution
of these lesions within the glomerulus and the initial sparing
of some glomeruli that warrant the pathologic descriptor,
focal segmental glomerulosclerosis (FSGS).
In New York City, about two thirds of steroid-resistant
nephrotic syndrome (SRNS) patients display FSGS on renal
biopsy[3].InthesettingofSRNS,theselesionsareassociated
with high risk of progressive renal failure [4]. Collectively,
these children comprise nearly 15% of the dialysis and renal
transplant population in North America. However, the FSGS
lesion is not pathognomonic for a speciﬁc clinical entity but
rather reﬂects any process that leads to patchy irreversible
podocyte injury. In addition to the many disorders that
cause “secondary” glomerulosclerosis, children with steroid-
sensitive nephrotic syndrome (SSNS) may show mild FSGS
lesions at presentation or later when biopsied for develop-
ment of steroid resistance [5]. Yet, if steroid responsiveness
is documented at any time, patients rarely have progressive
renal insuﬃciency [6–11]. Conversely, some children with
SRNS display only minimal histopathologic changes on
initial biopsy, yet eventually develop end-stage renal disease.
Thus, it has been diﬃcult to dissect out the discrete clinical
syndromesinchildrenwhopresentwithidiopathicnephrotic
syndrome in childhood.
Among the SRNS patients who develop FSGS lesions
and end-stage renal disease, about one third are now known
to harbor mutations of genes encoding components of the
podocyte slit diaphragm or adaptor proteins which link this
structure to the podocyte cytoskeleton. These patients are
generally unresponsive to immunosuppressive therapy but
do very well after renal transplantation. Among children2 International Journal of Nephrology
without pathogenic mutations of slit diaphragm genes, 30–
50% exhibit recurrence of proteinuria and then gradually
develop de novo FSGS lesions in the renal allograft. This
phenomenon, ﬁrst reported by Rich [12]a n dt h e nH o y e r
et al. [13], is generally taken as prima facie evidence for a
circulating “FSGSfactor” in the allograft recipient and serves
as the signature for a distinct form of SRNS. Capitalizing
on recent studies which screen out the most common gene
mutations, this review focuses on the natural history and
pathogenesis of steroid-resistant recurrent FSGS (R-FSGS).
2.ClinicalCharacteristicsof
RecurrentFSGS(R-FSGS)
Recurrence of FSGS in a subset of renal allografts has been
extensively documented. However, until recently, it has been
perplexing why some cases of primary FSGS recur while
others do not. With broader screening for the recessive
forms of genetic FSGS, the natural history of R-FSGS is now
emerging with greater clarity. At one point, it was suggested
thatR-FSGSpatientsmightdiﬀerfromchildrenwithsteroid-
responsive nephrotic syndrome only in that the former carry
a heterozygous mutation of a slit diaphragm gene. However,
this does not seem to be the case [14]. In general, R-FSGS
children have no identiﬁable mutations of slit diaphragm
genes including nonpathogenic variants such as the R229Q
polymorphism of the podocin gene [15, 16].
In 2010, Canaud reviewed 77 cases of idiopathic steroid-
resistant nephrotic syndrome with FSGS who received a
renal allograft [17]; the 42 patients who exhibited recurrent
proteinuricdisease hadnodemonstrableslitdiaphragm gene
mutations. Age at the time of presentation (10.4 ± 10 years)
and delay before end-stage renal disease (4.8 ± 2.3 years)
was similar to the group that showed no recurrence of
proteinuria. At initial presentation, all were steroid resistant
but 10/77 showed only minimal changes on renal biopsy.
In the others, the FSGS lesion was subclassiﬁed according
to 2004 “Columbia” criteria [18]; about half had a non-
speciﬁc (NOS) lesion, 22.2% had the cellular variant, 12.9%
showed collapsing lesions, and 7.8% had perihilar, and 7.8%
had “tip lesions.” Thus, there is no distinctive pathologic
subtype that distinguishes R-FSGS from forms of FSGS that
do not recur after transplantation. Furthermore, as FSGS
lesions gradually appeared in the allograft, less than 10%
showed the same Columbia pattern as in the initial biopsy.
In an earlier study of 19 R-FSGS patients, greater ﬁdelity of
the pathologic subtype before and after transplantation was
reported [19], but it seems most likely that the glomerular
histopathology reﬂects variability in the host response to
podocyte injury or to modiﬁcations induced by treatment
ratherthan a recognizable marker ofthe underlying etiology.
Clinical features of R-FSGS in the allograft roughly reca-
pitulate the initial presentation. However, recurrence aﬀords
an opportunity to dissect the features of the earliest stage
in detail. Heavy proteinuria may develop within hours of
transplantation; this occurs in the absence of any FSGS
lesions. Although proteinuria may rarely be delayed for sev-
eral months (1/42), the majority in Canaud’s study exhibited
proteinuria within 48 hours (32/42) or within the ﬁrst three
weeks (9/42) [17]. About 90% of R-FSGS patients exhibit
glomerulosclerosiswhen theyﬁrst cometo medical attention
[17], but it is clear that FSGS lesions appear gradually in the
allograft. Canaud identiﬁed FSGS in one patient by day 15
but documented the lesion in 28% of biopsies at 3 months
and 38% by 12 months after transplant [17]. Appearance
of FSGS lesions might have been more rapid in the absence
of plasmapheresis and high-dose calcineurin inhibitors, but
it seems that irreversible podocyte damage takes time and
occurs well after the disruption of podocyte slit diaphragms
that marks rapid onset of proteinuria.
3.The PutativeCirculatingPodocyte-Toxic
Factor in R-FSGS
There is little doubt that patients with R-FSGS have acquired
a circulating factor (or factors) that rapidly aﬀects podocyte
biology. Electron microscopy shows podocyte eﬀacement at
the time of recurrent proteinuria in the allograft and if pa-
tient plasma is applied to human podocytes in vitro,t h ec e l -
lularcytoskeletonis derangedwithin 6hours [3, 20].Sharma
et al. argued that podocyte dysfunction in R-FSGS could be
due to lack of a normal circulating factor, since replacement
of FSGS plasma with normal plasma allows podocyte cyto-
skeleton recovery in vitro [21]. However, R-FSGS is tran-
siently responsive to plasmapheresis [22]; this eﬀect can be
seen even when albumin (rather than fresh plasma) is used
as the replacement ﬂuid (Figure 1). Furthermore, Lagrue
et al. reported the case of a woman, who had previously
given birth to a normal child, and then developed SRNS
with FSGS lesions [23]. In her two subsequent pregnancies,
heavy proteinuria was evident in each newborn but resolved
within 2-3 weeks [23]. This interesting observation shows
that the FSGS factor can cross the placenta and suggests that
podocytes can recover once exposure to the factor is ended.
On the other hand, it also suggests that the circulating factor
can persist for many days in the infant circulation or that
podocytes need some time to recover.
For many years, it has been assumed that the putative
circulating factor is a cytokine derived from T-lymphocytes.
This hypothesis was proposed by Shaloub in 1986, when
he encountered a man with relapsing nephrotic syndrome
and leukemia, involving a malignancy of natural killer-like
T-lymphocytesbearingachromosome 10translocation; pro-
teinuria resolved following successful chemotherapy of the
malignancy [24]. Supporting this idea, Le Berre et al. re-
ported that Buﬀalo/Mna mice develop a spontaneous form
of R-FSGS which is ameliorated by infusion of CD4+CD25+
FoxP3+ lymphocytes or by LF15-0195, a drug that increases
the level of these cells in the circulation [25]. Similarly, Bao
etal.foundthatR-FSGS,inducedin micebyanantipodocyte
antibody, is linked to a decay activating factor-dependent T-
cell response [26]. However, recent reports have documented
aneﬀectoftheCD20B-cellantibody,rituximab,onrelapsing
steroid-dependent nephrotic syndrome [27–29], and Bagga
described an eﬀect of rituximab on steroid-resistant FSGS
[30]. Thus, the time-honored assumption that human R-
FSGS is a direct consequence of T- lymphocyte dysfunction
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Figure 1: Immediate recurrence of FSGS (rFSGS) following de-
ceased donor kidney transplantation. A 15-year-old girl with ster-
oid-resistant FSGS had bilateral nephrectomy prior to transplan-
tation. Proteinuria recurred within the ﬁrst 12 hours but was con-
trolled withintensiveplasmaexchange therapy(1.5plasmavolumes
with albumin replacement). Eﬀorts to wean plasmapheresis lead to
a rise in urine protein/creatinine ratio (g/g) on several occasions.
Each triangle represents a plasma exchange.
Several groups have tried to identify circulating pod-
ocyte-toxic factors in patients with nephrotic syndrome.
Savin and Sharma reported a 30–50kDa factor in FSGS
serum which appears to alter the permeability of isolated rat
glomerulitoalbumin,afterexposure to2%patientserumfor
10 minutes [31, 32]. In this assay, the investigators measured
the increase in glomerular volume that accompanies switch
of culture medium from 5g/L to 1g/L albumin; unfortu-
nately, it is diﬃcult to know whether this assay reﬂects a
change in permeability of the slit diaphragm or the capil-
lary wall. In other reports, hemopexin, cardiotropin-like
cytokine1, and soluble urokinase receptor have been pro-
posed as potential candidates, but direct evidence for their
involvement in R-FSGS is lacking to date.
Most recently,Weietal. reportedthatplasma levelsofthe
soluble urokinase plasminogen activating receptor (suPAR)
are elevated above an apparent threshold level (>3ng/mL)
in about two thirds of steroid-resistant FSGS patients and
that suPAR induces proteinuria 24 hours after infusion
into mice [33]. In elegant experiments with various suPAR
mouse mutants, they found that this involves binding to and
activation of β3integrin at the podocyte surface. In previous
studies, they showed that β3 i n t e g r i na c t i v a t i o np r o m o t e sc e l l
mobility via small GTPases (Cdc42 and Rac1) that aﬀect
the cytoskeleton and showed that constitutive activation
of β3integrin causes proteinuria [33]. These observations
strongly implicate suPAR-induced β3integrin activation as
a central mechanism causing proteinuria in FSGS. It is
puzzling, however, why one third of their FSGS cohort had
suPAR levelswithin thenormal range(1–3ng/mL).Conceiv-
ably, these patients have another circulating factor that
stimulates local uPAR production by the podocyte or they
may have some other, as yet unknown, circulating FSGS fac-
tor. Another paradox is that patients with chondrosarcoma
produce elevated plasma levels of suPAR but uniformly do
not develop proteinuria [34]. Wei et al. postulated that the
suPAR released by chondrosarcoma cells may be functionally
diﬀerent due to alternative protein processing [33]. While
some perplexing questions remain, activation of podocyte
β3integrin by circulating suPAR may be central to the patho-
genesis of R-FSGS.
In 2009, Leroy et al. reported the case of a 12-year-
old boy with R-FSGS in whom infusion of anti-TNF-alpha
antibody induced rapid but transient complete remission.
Remission was transient, but with each relapse, proteinuria
resolved after infusion of etanercept, a synthetic fusion
protein that blocks TNF alpha interaction with its receptor
[35, 36]. In a preliminary report from the FONT study
group, two of nine children with R-FSGS exhibited complete
remission of proteinuria [35]. In an interesting case report,
Assadi described a pregnant woman with HELLP syndrome
(hemolysis, thrombocytopenia, elevated liver enzymes) and
elevated circulating levels of TNF-alpha, whose newborn
baby had nephrotic syndrome that resolved postnatally [37];
although the baby received hydrocortisone, the authors
argue that transient proteinuria was most likely the result
of transplacental TNF-alpha, since levels of the cytokine
fell in parallel with resolution of proteinuria. TNF-alpha is
expressed bylymphocytesand monocytes; podocytesexpress
TNF-alphaR2receptorsandrespond tocytokinestimulation
by producing TNF-alpha themselves [38]. These observa-
tions suggest that in some cases of R-FSGS, TNF-alpha may
constitute another circulating factor driving podocyte injury
and raises some interesting questions about its relationship
to the suPAR/β3integrin pathway.
4.PathogenesisofProteinuriaand FSGS
Lesionsinthe AffectedAllograft
The eﬀect of R-FSGS serum on the allograft glomerular ﬁl-
tration barrier is rapid and it is not uncommon to identify
proteinuria in the immediate postoperative period [17].
Similarly, R-FSGSplasma disturbs thepodocytecytoskeleton
within hours in vitro [39, 40]( Figure 2). These actin-based
ﬁbers are crucial for support of podocyte foot processes
and, in biopsies performed shortly after transplantation,
foot process eﬀacement is seen by electron micrography.
Furthermore, the actin cytoskeleton is linked indirectly via
scaﬀold proteins to the slit diaphragm complex and, in vitro,
R-FSGS plasma disperses nephrin from the slit diaphragms
[20, 39, 41]. Interestingly, however, recurrence of proteinuria
is sometimes delayed for weeks [17]. It is unclear whether
late onset of recurrent proteinuria in the allograft represents
a less aggressive form of the disease or whether primary
progression of proteinuria was slower in such patients.
Asnoted above,there isoftenconsiderabledelaybetween
the onset of proteinuria and the gradual appearance of FSGS
histopathologic lesions in the allograft. Current evidence
supports the view that patchy irreversible injury to the
glomerulus is preceded by podocyte detachment from the
GBM [42–45]. FSGS plasma has been shown to disperse
nonmuscle myosin from actin stress ﬁbers in vitro [41].
Conceivably, loss of this contractile element in the podocyte
cytoskeleton contributes to detachment by compromising
cell contractility during pulsatile blood ﬂow through the








































Figure 2: Plasmapheresis eﬄuent from a patient with a recurrent FSGS disrupts the cytoskeleton of human podocytes in culture. Immor-
talized human podocytes (gift from Dr. Saleem) were incubated for 6 hours with 10% plasmapheresis eﬄuent from a control patient
undergoing plasmapheresis for a nonrenal disease (upper panel); PPE from a patient with recurrent FSGS collected at the start of procedure
(middle panels, “early PPE”); end of plasmapheresis (lower panels, “late PPE”). The “early PPE,” but not the late PPE FSGS sample disrupts
polymerized actin (phalliodin staining,red) and nonmusclemysosinII (stainingwith anti-MYH9 antibody-green); arrowheads: actin stress
ﬁbers; scale bar 5mc.
detachment is disruption of focal adhesion complex pro-
teins at the podocyte’s basolateral surface. Chen reported
that podocyte detachment and podocyturia is associated
with decreased integrin expression in FSGS patients [16].




from the glomerular basement membrane may be driven by
the same circulating factor that rapidly causes proteinuria
in the allograft, it has been diﬃcult to understand why
histopathologic lesions appear only after months or years.
Some insight into this paradox has recently come from two
converging lines of investigation that assign an important
role to the host response to podocyte injury in determin-
ing the long-term outcome. In 2005, Dijkman performed
detailed analysis of a patient with R-FSGS, in whom
Bowman’s space and the glomerular tuft were “invaded” by
parietal epithelial cells [46]. Several groups have provided
strong support for the hypothesis that glomerular epithelial
cells seen in the “proliferative” form of FSGS are derived
from Bowman’s capsule rather than arising through trans-
diﬀerentiation of mature podocytes as had been proposed
earlier[47–49].Thesecondsetofimportantobservationshas
come from Romagnani’s group who have shown that mature
kidneys retain a subset of renal progenitor cells in a putative
stem cell niche at the urinary pole of Bowman’s capsule.
Their observations provide indirect evidence that these pro-
genitor cells replace damaged podocytes throughout life.
Taken together these two sets of observations raise the inter-
esting possibility that FSGS lesions represent a disturbance
of the normal process of podocyte replacement—occurring
either when the system is overwhelmed by the magnitude
of podocyte detachment or dysregulated by the circulating
factor itself. In this view, proteinuria may reﬂect that imme-
diate eﬀect of the FSGS factor on podocytes, but the gradual
appearance of glomerular lesions reﬂects insuﬃciency of the
normal podocyte replacement process.
5.TreatmentofR-FSGS
AlthoughR-FSGSmaybedrivenbyadisorderoftheimmune
system, the prospect of achieving sustained remission with
immunosuppressive agentsaloneislimited.(a)MostR-FSGS
patients were treated unsuccessfully with immunosuppres-
sive agents (usually prednisone and calcineurin inhibitors ±
cyclophosphamide for the primary disease in their native
kidneys). (b) FSGS recurs in the allograft despite standard
transplant immunosuppression. However, numerous groups
have reported a rapid eﬀect of plasmapheresis on proteinuriaInternational Journal of Nephrology 5
in some patients with R-FSGS [50]. When plasmapheresis
is initiated shortly after disease recurrence, proteinuria im-
provessubstantiallyorresolvesinuptothreequartersofchil-
dren;typicallythisinvolvesthreeorfour1.5xplasmavolume
exchanges per week for several weeks [51].
Unfortunately, many children who show excellent initial
response to plasmapheresis recur as the frequency of treat-
ments is weaned. In these children, a variety of sustained im-
munosuppressive regimens have been tried. Salomon re-
ported rapid and sustained remission of R-FSGS in 30% of
children treated with higher doses of calcineurin inhibitors
(troughlevelsof250–300ng/mL for3weeks),proposing that
this might overcome the eﬀect of hyperlipidemia on down-
regulation of LDL receptors that mediate cellular uptake of
the drug [52] .R e m i s s i o nw a se v e nh i g h e r( 7 0 % )a m o n g
children who also received intensive plasmapheresis [52]. In
a pilot study of adults with R-FSGS, Canaud used a com-
bination of high dose (2mg/kg by intravenous infusion for
2 weeks, plus oral cyclosporine to achieve 2-hour levels of
1200–1400ng/mL,thereafter)andprotractedplasmapheresis
(1.5-plasma volume exchanges against albumin X3/week
for three weeks with slowly decreasing frequency over
nine months). With this protocol, sustained remission was
achieved in nine of ten patients [22]. Dall’Amico et al.
reported sustained remission in 7 of 11 patients treated with
plasmapheresis and oral cyclophosphamide 2mg/kg/day for
2-3 months [53]. Interestingly, among 30 reported cases
of R-FSGS, about 50% have been reported to undergo
sustained complete urinary remission following administra-
tion of one or two doses of rituximab 375mg/m2 [54–56].
It is unclear whether the infusion of anti-CD20 antibody
eliminates production of the circulating FSGS factor by B-
cells, whether the depletion of B-cells indirectly alters T-cell
function, or whether rituximab acts directly on podocytes
[57].
6.Conclusion
About 30–50% of children with steroid-resistant nephrotic
syndrome developrapid recurrent proteinuria and thereafter
developslowlyprogressiveFSGSintheirallografts.Recurrent
FSGS deﬁnes a distinct clinical entity involving a putative
circulating factor that rapidly disrupts the podocyte slit
diaphragm and then leads to irreversible podocyte injury.
Until proven otherwise, it should be presumed that the
pathogenesis of R-FSGS is distinct from steroid-sensitive
idiopathic nephrotic syndrome and that heterozygous muta-
tions of slit diaphragm genes have little impact on clinical
features of the disease.
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